Idiopathic Pulmonary Fibrosis Market Poised to Reach US$ 6,736.49 Million by 2035 as Late-Stage Pipelines and Novel Mechanisms Transform Treatment Outcomes | Astute Analytica
Idiopathic pulmonary fibrosis represents a high need specialty market, with global IPF drug sales of roughly USD 3 billion and single digit CAGR driven by rising prevalence, better diagnosis, and premium pricing of antifibrotics like pirfenidone and nintedani…
Chicago, Feb. 09, 2026 (GLOBE NEWSWIRE) -- The global Idiopathic pulmonary fibrosis market generated US$ 2,970.69 million in 2025 and is estimated to reach US$ 6,736.49 million by 2035, growing at a … [+14507 chars]